​​​​​​​MINDCURE (CSE: MCUR | OTCQB: MCURF) Announces Manufacturing of Synthetic Ibogaine to be utilized in business’s Clinical analysis

MINDCURE Announces Manufacturing of Synthetic Ibogaine to be utilized in business’s Clinical Research

The Company expects to own ibogaine manufactured plus in usage for research by Q4.

VANCOUVER, BC, March 3, 2021 /CNW/ – Mind Cure wellness Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) a frontrunner in advanced proprietary technology for psychedelic medication breakthrough, is happy to announce it has started 1st phase of manufacturing pharmaceutical grade ibogaine to be utilized in preclinical and medical research.

Ibogaine is a naturally occurring compound that is psychoactive from the root of the Tabernanthe iboga shrub, native of the Congo and Gabon.1 The compound offers potential that is therapeutic substance usage problems, and it is advertised become being among the most effective anti-addiction medications, particularly if used in combination with appropriate guidance and help. But, normal sourced elements of ibogaine are exceedingly restricted as these flowers have reached threat of extinction because of the growing demand that is global environmental pressures threatening their natural habitat.

MINDCURE Recognizes the importance of sustainability, excellence, and reliability regarding the materials it uses in product research and development. By manufacturing ibogaine, MINDCURE’s research group has use of a predictable and standardized method of getting artificial ibogaine, while ensuring dosing that is consistent reliable results.

Ibogaine has unique and broad actions in the brain, affecting multiple receptors and systems that are neurotransmitter. In addition to inducing effective effects that are subjective research indicates ibogaine may help repair and rewire addiction-related neural pathways.2 Emerging evidence of its neuroprotective effects, as well as its ability to boost brain neurotrophic factors and neuroplasticity processes supports research that is future the application of ibogaine and derivatives thereof for any other indications, including within the remedy for neuropathic discomfort and neurodegenerative conditions, such as for example Parkinson’s and Alzheimer’s infection.3 While ibogaine showcases an extensive apparatus of action, possible poisoning, and low bioavailability which might preclude ibogaine’s effectiveness in dealing with neurodegenerative problems, MINDCURE will dutifully design any research efforts in recognition of the facts.

“Ibogaine is among a couple of psychoactive alkaloids based in the iboga plant. Ibogaine provides incredible potential that is therapeutic especially in the context of neuroregeneration,” said Dr. Ryan Hartwell, Chief Science Officer, MINDCURE. “Manufacturing ibogaine gives us the ability to pursue promising research avenues and obtain high-quality results, without threatening the existence of the plant and limiting the natural supply of an amazing psychedelic.”

About Mind Cure Health (MINDCURE) Inc.

MINDCURE exists as a response to the current health that is mental and urgent requires effective remedies. MINDCURE thinks into the have to reinvent the psychological state care model for clients and professionals to permit psychedelics to advance into typical and accepted care.

MINDCURE is focused on distinguishing and developing paths and products which simplicity suffering, enhance productivity, and enhance health that is mental. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve health that is mental

On Behalf regarding the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news launch may represent “forward-looking information” inside the meaning of relevant securities laws and regulations (also referred to as forward-looking statements). Forward-looking information involves understood and unknown dangers,
uncertainties along with other facets, that can cause real outcomes, performance or achievements or industry outcomes, become materially distinctive from any future outcomes, performance or achievements or industry outcomes expressed or suggested by such information that is forward-looking. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific information that is forward-looking this news launch includes, it is not restricted to, statements with regards to: MINDCURE production ibogaine; ibogaine getting used in MINDCURE’s preclinical and medical trials; MINDCURE’s group creating a predictable method of getting artificial ibogaine to operate a vehicle dependable outcomes and constant doses; and MINDCURE dutifully creating any research efforts in recognition of ibogaine’s wide apparatus of action, possible poisoning, and low bioavailability which might preclude ibogaine’s effectiveness in dealing with neurodegenerative problems.

Forward-looking info is according to lots of key objectives and presumptions produced by MINDCURE, including, without limitation: the COVID-19 impact that is pandemic the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; manufacturing ibogaine will help MINDCURE achieve its research goals; and MINDCURE will be able to operate its business as planned. Although the information that is forward-looking in this news launch relies upon exactly what MINDCURE thinks become reasonable presumptions, it cannot ensure investors that real outcomes is likely to be in keeping with such information.

Forward-looking info is given to the goal of presenting details about administration’s present objectives and plans associated with the near future and readers are cautioned that such statements might not be right for other purposes. Forward-looking information involves significant dangers and uncertainties and may never be read as an assurance of future performance or outcomes as real outcomes may vary materially from those expressed or suggested such information that is forward-looking. Those risks and uncertainties include, among other things, risks related to: the impacts of the pandemic that is COVID-19 the Canadian economy, MINDCURE’s industry and MINDCURE’s company, which might adversely affect, that can continue steadily to negatively effect, MINDCURE that can materially adversely influence MINDCURE’s assets, outcomes of operations, economic condition, and MINDCURE’s capability to get extra equity or financial obligation funding, and satisfy its obligations; basic fiscal conditions; future development potential; competition for psychological state and health investments; production ibogaine might not assist MINDCURE attain its research objectives; and alterations in legislation or laws. Management thinks that the objectives reflected within the forward-looking information included herein are based on reasonable presumptions and information available; nevertheless, administration will give no assurance that real outcomes is likely to be in keeping with such information that is forward-looking. Additional information on the risk factors that could affect MINDCURE can be found under “Risk Factors” in MINDCURE’s final prospectus which is available on SEDAR at www.sedar.com.
The forward-looking information contained herein is expressly qualified in its entirety by this statement that is cautionary. Forward-looking information reflects administration’s present philosophy and it is according to information available to MINDCURE. The information that is forward-looking stated as of the date of this news release and MINDCURE assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.
The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the accuracy or adequacy of the launch.

1 Ignacio Carrera, “the way the Psychedelic Ibogaine May Heal, Repair & Safeguard the mind,” Chacruna (2018), https://chacruna.net/ibogaine-heal-repair-protect-brain/.
2 february Soledad Marton et al., “Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits,” Frontiers in Pharmacology 10 (May 2019), https://doi.org/10.3389/fphar.2019.00193.
3 Soledad Marton et al., “Ibogaine management Modifies GDNF and BDNF Expression in Brain Regions taking part in Mesocorticolimbic and Nigral Dopaminergic Circuits.”

SOURCE Mind Cure wellness Inc.
For more info:

Connect: Investor Relations: [email protected]; 1-888-593-8995; Jonathan L. Robinson CFA, Partner, Oak Hill Financial Inc., [email protected], 16-669-1001

Source: https://www.newswire.ca/news-releases/mindcure-announces-manufacturing-of-synthetic-ibogaine-to-be-used-in-company-s-clinical-research-814181451.html

Disclosure: Mind Cure is a customer of Psychedelic Stock Watch(*)

Latest posts